Compound index

Incretin & Metabolic Receptor Agonists

Semaglutide

Also known as Ozempic · Wegovy · Rybelsus

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

Overview

A modified GLP-1 receptor agonist used in specific FDA-approved medicines.

Regulatory status

FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.

  • Ozempic · Type 2 Diabetes

    Glycemic control in adults with type 2 diabetes, with diet and physical activity.

    Authoritative label record
  • Wegovy · Weight Management

    Long-term weight reduction in adults with obesity, or overweight with a weight-related condition; the indicated product also covers patients 12 and older with obesity.

    Authoritative label record
  • Wegovy · Cardiovascular Risk

    Major cardiovascular event risk reduction in adults with established cardiovascular disease and overweight or obesity.

    Authoritative label record
  • Wegovy injection · Liver Disease

    Treatment of noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3) in adults; accelerated approval based on a surrogate endpoint, with confirmation of clinical benefit required.

    Authoritative label record

Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

WADA prohibited status: current list and context

Evidence at a glance

Large randomized trials support product-specific indications; results depend on the population, endpoints and approved formulation.

Key sources

Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.

Related compounds

  • Retatrutide

    Same scientific class · A 39-amino-acid chain. · Late-stage human trials

  • Tirzepatide

    Same scientific class · A 39-amino-acid chain. · FDA-approved for specific indications

Related glossary terms